Estudo randomizado | Abiraterona e olaparibe para câncer de próstata metastático resistente à castração.

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer – NEJM Evidence

Comentário no Twitter

Combination treatment with abiraterone and olaparib increased progression-free survival regardless of homologous recombination repair gene mutation status in patients with metastatic castration-resistant #ProstateCancer treated in the first-line setting. https://t.co/CAUDF2ZErG pic.twitter.com/YARZa8AUXJ

— NEJM Evidence (@NEJMEvidence) June 3, 2022